BioSpace News Archive

Dyne Therapeutics, Inc. today reported financial results for the second quarter of 2022 and business highlights.

KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 11, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the second quarter 2022.

Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics’ completed clinical trials in ALS including, BENEFIT-ALS.

Purple Biotech Ltd. today announced financial results for the second quarter ended June 30, 2022.

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2022.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022.

Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter ended June 30, 2022.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), today announced that members of management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference on Tuesday, August 9 at 12 p.m. ET and host investor meetings

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022.